63 related articles for article (PubMed ID: 8822599)
1. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation.
Alhenc-Gelas M; Aillaud MF; Bonvarlet MN; Dupuy G; Juhan-Vague I; Aiach M
Thromb Haemost; 1996 Jun; 75(6):976-7. PubMed ID: 8822599
[No Abstract] [Full Text] [Related]
2. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
3. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
4. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
6. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
7. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
Taylor LJ; Oster RA; Fritsma GA; Tichenor PH; Reed CE; Eiland BM; Hudson CL; Marques MB
Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
[TBL] [Abstract][Full Text] [Related]
8. Further evidence that activated protein C resistance affects protein C coagulant activity assays.
Jennings I; Kitchen S; Cooper PC; Rimmer JE; Woods TA; Preston FE
Thromb Haemost; 2000 Jan; 83(1):171-2. PubMed ID: 10669173
[No Abstract] [Full Text] [Related]
9. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
10. A fast and robust dual-label nonradioactive oligonucleotide ligation assay for detection of factor V Leiden.
Chakravarty A; Hansen TS; Hørder M; Kristensen SR
Thromb Haemost; 1997 Oct; 78(4):1234-6. PubMed ID: 9364990
[TBL] [Abstract][Full Text] [Related]
11. Clinical features in 36 patients homozygous for the ARG 506-->GLN factor V mutation.
Emmerich J; Alhenc-Gelas M; Aillaud MF; Juhan-Vague I; Jude B; Garcin JM; Dreyfus M; de Moerloose P; Le Querrec A; Priollet P; Berruyer M; Vallantin X; Wolf M; Aiach M; Fiessinger JN
Thromb Haemost; 1997 Apr; 77(4):620-3. PubMed ID: 9134631
[TBL] [Abstract][Full Text] [Related]
12. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.
Nowak-Göttl U; Sträter R; Dübbers A; Oleszuk-Raschke K; Vielhaber H
Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390
[TBL] [Abstract][Full Text] [Related]
13. The use of two different APC resistance assay systems provides optimal sensitivity and specificity for diagnosing genetic APC resistance.
Solano C; Hogg AL; Saal RJ; Scott DC; Cobcroft RG
Blood Coagul Fibrinolysis; 1997 Jul; 8(5):268-73. PubMed ID: 9282790
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Strandberg K; Svensson PJ; Ohlin AK
Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
[TBL] [Abstract][Full Text] [Related]
15. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study.
Toulon P; Smirnov M; Triscott M; Safa O; Biguzzi E; Bouziane K; Tripodi A
Thromb Res; 2009 May; 124(1):137-43. PubMed ID: 19157524
[TBL] [Abstract][Full Text] [Related]
16. [A novel assay for detecting the thrombomodulin-protein C/S anticoagulant pathway using human thrombomodulin (prothrombinase assay)].
Mohri M; Sata M; Gomi K; Maruyama Y; Osame M; Maruyama I
Rinsho Byori; 1997 Feb; Suppl 104():203-4. PubMed ID: 9128383
[No Abstract] [Full Text] [Related]
17. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
Toulon P
Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of factor V: Q506 mutation using whole blood protein C resistance.
Sacchi E; Duca F; Tagliabue L
Blood Coagul Fibrinolysis; 1996 Nov; 7(8):799-800. PubMed ID: 9034562
[No Abstract] [Full Text] [Related]
19. [Factor V Leiden and activated protein C resistance].
Cauchie P; Hilbert P
Rev Med Brux; 1997 Jun; 18(3):97-102. PubMed ID: 9273603
[TBL] [Abstract][Full Text] [Related]
20. Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
Giordano P; Sabato V; Schettini F; De Mattia D; Iolascon A
Haematologica; 1997; 82(6):698-700. PubMed ID: 9499670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
